Blueshift Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Blueshift Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$296K	Sell	9,422 -5,410	-36%	-$160K	0.07%	379
2026 Q1	$367K	Buy	+14,832	New	+$353K	0.11%	285
2022 Q2	–	Sell	-10,941	Closed	-$91K	–	736
2022 Q1	$91K	Buy	+10,941	New	+$77.3K	0.01%	772
2020 Q1	–	Sell	-56,554	Closed	-$212K	–	288
2019 Q4	$212K	Buy	+56,554	New	+$264K	0.02%	705

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Blueshift Asset Management's CPRX Position: Q2 2026 in Review

Blueshift Asset Management reduced its Catalyst Pharmaceutical (CPRX) stake by 36% in Q2 2026, selling an estimated $160K and leaving 9,422 shares worth $296K. The position accounts for 0.07% of the portfolio, ranked #379.

Blueshift Asset Management first reported a position in CPRX in Q4 2019 and has held it in 4 quarters since. The position peaked at $367K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Blueshift Asset Management held 9,422 shares of Catalyst Pharmaceutical worth $296K as of Q2 2026.
Blueshift Asset Management sold 5,410 Catalyst Pharmaceutical shares in Q2 2026, an estimated $160K.
Catalyst Pharmaceutical made up 0.07% of Blueshift Asset Management's portfolio in Q2 2026, its #379 holding.
Blueshift Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2019 and has held it in 4 quarters since.
Blueshift Asset Management's Catalyst Pharmaceutical position peaked at $367K in Q1 2026.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Blueshift Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.